KALA KALA
Company Profile ↓Company Overview
KALA (KALA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.81% |
| 6 Months: | -97.02% |
| 3 Months: | -87.48% |
| 1 Month: | -53.58% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.82 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 1.39M | 2.06M | 1.45M | 1.18M | 1.07M | 833.00K | 2.22M | 2.24M | 3.27M | 3.05M | 3.07M | 1.37M | 2.10M | 420.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -9.65M | -9.75M | -9.57M | -9.63M | -9.53M | -11.14M | -14.52M | -15.50M | -24.05M | -22.41M | -21.57M | - | -20.12M | -21.28M | -25.84M | - | -28.31M | -29.05M | -26.07M | -30.91M | -25.97M | -14.57M | -11.68M | -9.60M | -8.76M | -11.93M | -9.61M | -9.99M | -10.67M | -11.03M | -7.24M | -1.80M |
| Net Income | - | - | - | - | - | -11.30M | -14.62M | -15.60M | -25.39M | -23.82M | -23.18M | - | -21.95M | -23.31M | -27.95M | - | -30.41M | -36.50M | -28.13M | -32.94M | -28.11M | 29.07M | -14.46M | -10.41M | -8.70M | -11.81M | -9.58M | -8.95M | -8.95M | -11.15M | -7.56M | -1.62M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.57 | -21.41 | -22.18 | -18.92 | 19.25 | -6.99 | -4.36 | -3.41 | -4.20 | -3.16 | -1.93 | -70.49 | -1.71 | -1.07 | -0.14 |
| R&D Expense | 5.95M | 8.26M | 8.04M | 8.07M | 7.02M | 5.66M | 7.37M | 7.03M | 6.96M | 7.11M | 7.07M | - | 5.43M | 6.05M | 3.47M | - | 3.13M | 3.09M | 2.88M | 4.47M | 4.47M | 5.39M | 4.04M | 4.28M | 5.55M | 6.35M | 5.32M | 5.17M | 6.05M | 6.23M | 6.13M | 61.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.00K | 0 | 0 | - | 6.07M | 6.36M | 11.24M | 3.89M | 0 | 0 | 0 |
| Operating Income | -15.95M | -32.67M | -39.88M | -64.72M | -88.22M | -96.23M | -130.25M | -81.71M | -39.66M | -40.98M | -39.16M |
| Net Income | -16.68M | -33.17M | -42.21M | -66.74M | -94.35M | -104.33M | -142.60M | -44.82M | -42.20M | -38.51M | -26.98M |
| Diluted EPS | - | - | - | - | - | -1.99 | -108.32 | -29.48 | -17.35 | -10.15 | -3.31 |
| R&D Expense | 11.38M | 25.03M | 29.01M | 29.29M | 27.27M | 18.35M | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 46.33M | 116.55M | 220.97M | 154.32M | 221.61M | 139.43M | 86.82M | 55.95M | 55.48M | 9.49M |
| Total Equity | -40.72M | -56.66M | -87.76M | 89.68M | 104.98M | 29.69M | 100.00M | 16.80M | 18.97M | 7.50M | 12.33M | 7.00M |
| Cash & Equivalents | - | - | - | - | - | 85.45M | 77.26M | 92.14M | 70.50M | 50.90M | 51.18M | 7.56M |
| Long Term Debt | - | - | 9.10M | 11.99M | 70.23M | 71.18M | 72.24M | 78.93M | 37.94M | 34.19M | 20.10M | - |
| Total Liabilities | - | - | 15.70M | 26.87M | 115.99M | 124.63M | 121.61M | 122.62M | 67.85M | 48.45M | 43.15M | 2.49M |
| Current Liabilities | - | - | 5.55M | 14.87M | 17.01M | 24.77M | 22.23M | 37.42M | 25.68M | 8.35M | 16.96M | 2.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -15.09M | -27.35M | -34.10M | -54.12M | -92.72M | -90.69M | -108.23M | -78.91M | -27.93M | -29.38M | -31.99M |
| Investing Cash Flow | -252.00K | -153.00K | -480.00K | -1.58M | -1.33M | -78.21M | 70.80M | 62.72M | -429.00K | -208.00K | -15.00K |
| Financing Cash Flow | 10.48M | 67.21M | 103.70M | 124.10M | 8.98M | 160.63M | 42.55M | -7.94M | 8.51M | 29.88M | -11.62M |
| Capital Expenditure | -252.00K | -153.00K | -480.00K | -1.58M | -1.33M | - | - | - | - | - | - |
| Free Cash Flow | -15.34M | -27.50M | -34.58M | -55.70M | -94.06M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -35,435.6% | - | - | - | -1,452.5% | -1,512.6% | -1,158.8% | -2,099.3% | - | - | - |
| Net Margin % | -37,071.1% | - | - | - | -1,553.3% | -1,639.8% | -1,268.7% | -1,151.6% | - | - | - |
| ROE % | 29.4% | 37.8% | -47.1% | -63.6% | -317.8% | -104.3% | -848.6% | -236.2% | -562.4% | -312.3% | -385.6% |
| ROCE % | - | -80.1% | -39.2% | -31.7% | -68.1% | -48.3% | -127.7% | -133.6% | -83.3% | -106.4% | -559.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KALA
KALA BIO Announces Reverse Stock Split - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPVERSQ2duT1JkeW1iZnR5Vk9pTjhVVEt5cnhrR01lOHhOblRKOEd3ZkNLNXJtbU1qd0VVVHVJeDZPcU5jdnJuNWdBVVlpMDh6NEoxSm43Wkx3dDlLb0xqazVBNkR5eWZxV2RfUHZVZXRaVldkdFhFY1NLLXc1bzdjbDVHbl9TOG8xZ24xWT…
KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark - Stocktwits
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOZnpYV0kwc0E4dGFPRXJ0QXlobTBOb2RnaGd3eTZXWTVtRXFaam83MlpfckpxdFhPUnBUbkFJWXhEZ0h3YmZGVFEyRUVuX0hyZHVnUGRuOW5jNld3eTlGX09ocGt4RHh4dmNwLXJwWXUyMTNaMG81UmZpOUd6MVUwODZZUm9JNmk5Mmt5d0…
KALA BIO cuts share count to 18.6M in 1-for-50 reverse split - Stock Titan
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNSHJfbjZsdHF5VXdOenpkVmx3c3pHbmZUdWFseFg0MGFBbXl5R09xME9nSS1Sb25SVGNsUFJnZFVCQ0d2TXNKUFNXTWRCRW1rZEtWYTZmT2xUOEJMMWs5bF91M1BOdXNtLTl3SG50MTNDN2xsWnl6b1hJUC1DY2hBVzI5RnVKUWVwSDBFUj…
Kala Bio announces 1-for-50 reverse stock split effective Friday - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNS0o3bklpV00xM2JDVV9NRnFZd21FRzd6ZGxYLUNUM2RhM0hoTHdRRWhEOFl1TTFFcFFPZ0h2RGZGUnl6OVItbEFrYWJ4aFlyNjl6aUs1MGN6bFBTRmU2b0NSOG1uMzVlSWtoMkpBeUdWNEh6WFpoWE42NUlRNlNIZ3VjeDM1cGtOY255a2…
Kala Bio's CHASE trial misses primary endpoint, KPI-012 development discontinued - Ophthalmology Times Europe
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNSmxHV05zdV9SM2M1UmwwUEl0Yi1zUGVnOWVjamROM0pMclBGUGFHRWhTQk0wQWdrNjdrSUNLRVNNcVNnd3ZPbjNfZGI5anJKVHZmN09HbjQ1SENGeTFZTTNCdmZ4VzF2LUVhMUFwS1UtamlXTXRhU1VEQmh6dDl4VVlCV01hYnhKZEt0SU…
KALA|KALA BIO Inc|Price:0.779|Chg%:+0.023 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFAxX0Z3VDVkT0hXVHVJSjlYYUF5VFpfd19UMUtlNDlZY24wSXd1TFlBRy1fVDhHb19PRm9wUHRaM3dYd0lpSF9mZkdVTDRKbThQM2lNbkpWWUVTZUNjSVhtckZZZFNPM3VnVE10TzFn?oc=5" target="_blank">KALA|KALA BIO Inc|P…
KALA — Frequently Asked Questions
What is the current share price of KALA?
As of 2026-08-05 17:25 PDT, KALA trades at $0.70 on NASDAQ/NYSE. Its 52-week range is $0.61 to $981.50.
What is the P/E ratio of KALA?
KALA trades at a trailing price-to-earnings (P/E) ratio of -0.21.
Is KALA a good stock to buy?
This page provides a data-driven analysis of KALA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.